GC Biopharma and Novelty Nobility Forge Joint Research Alliance
GC Biopharma has announced an exciting partnership with Novelty Nobility, a company focused on advanced antibody-based therapeutics, aiming to tackle geographic atrophy (GA), a severe complication related to age-related macular degeneration (AMD).
AMD is classified into two types: dry and wet. The dry type often progresses to geographical atrophy, a condition that severely impacts retinal health and can lead to blindness. Approximately 1.5 million people are affected by this debilitating condition in various developed regions.
Recently, the FDA approved a treatment for GA, but reports showed that while it slowed progression, it failed to restore vision lost due to the condition. Many patients also experienced adverse effects, including a shift to wet AMD or inflammation. This situation emphasizes the urgent need for more effective and safer therapeutic options for those suffering from GA.
The newly signed agreement between GC Biopharma and Novelty Nobility outlines a collaborative approach to research and develop innovative antibody-based therapeutics aimed at GA. The first phase of their collaboration will focus on identifying critical proteins involved in GA's development and selecting appropriate therapeutic candidates.
"Novelty Nobility has been dedicated to developing a next-generation treatment for wet AMD through our proprietary antibodies. Our collaboration with GC Biopharma allows us to build on our success and explore innovative treatments in the GA area," said Sang-gyu Park, CEO of Novelty Nobility. This partnership is expected to unite their strengths in antibody drug development and GC Biopharma's extensive experience in protein therapeutics.
Jaewook Jung, Head of Research and Development at GC Biopharma, added, "Combining our expertise could create breakthroughs in GA therapies. We’re excited to explore new therapeutic areas through this collaboration and aim to innovate beyond our traditional focus on plasma derivatives and rare diseases." This synergy could unlock potential new treatments for patients in dire need of effective care.
About GC Biopharma Corp.
GC Biopharma Corp., previously known as Green Cross Corporation, is a leader in biopharmaceuticals offering life-saving protein therapeutics and vaccines. With its headquarters in Yongin, South Korea, GC Biopharma has established itself as a top manufacturer of plasma proteins and vaccines, dedicated to providing high-quality healthcare solutions for over fifty years.
About Novelty Nobility Inc.
Novelty Nobility is a biotech company in clinical stages, committed to enhancing the lives of patients by developing novel antibody-based therapeutics. Known for its innovative antibody discovery platform (PREXISE-D), Novelty Nobility creates bispecific antibodies and antibody-drug conjugates (ADCs). While focusing primarily on oncology, the company also ventures into fields such as ophthalmology and immunology, aiming to make impactful contributions to medical science.
Frequently Asked Questions
What is the focus of the collaboration between GC Biopharma and Novelty Nobility?
The partnership aims to jointly research and develop antibody-based therapeutics for geographic atrophy, a condition related to age-related macular degeneration.
What is geographic atrophy, and why is it significant?
Geographic atrophy is a severe form of dry age-related macular degeneration, leading to retinal damage and potential blindness, affecting millions worldwide.
What challenges do current treatments for geographic atrophy face?
Current FDA-approved treatments have shown limited efficacy, only slowing progression without restoring vision, and have been associated with adverse side effects.
How do the companies plan to develop new therapies?
The companies will identify critical proteins involved in geographic atrophy and seek therapeutic candidates that target these proteins for enhanced treatment options.
What is the history of GC Biopharma?
GC Biopharma, formerly Green Cross Corporation, is a well-established biopharmaceutical company with a robust track record in producing plasma proteins and vaccines for over fifty years.
